Suzanne Klise

627 total citations
18 papers, 435 citations indexed

About

Suzanne Klise is a scholar working on Psychiatry and Mental health, Urology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Suzanne Klise has authored 18 papers receiving a total of 435 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Psychiatry and Mental health, 7 papers in Urology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Suzanne Klise's work include Urinary Bladder and Prostate Research (7 papers), Hormonal and reproductive studies (6 papers) and Advanced Breast Cancer Therapies (5 papers). Suzanne Klise is often cited by papers focused on Urinary Bladder and Prostate Research (7 papers), Hormonal and reproductive studies (6 papers) and Advanced Breast Cancer Therapies (5 papers). Suzanne Klise collaborates with scholars based in United States, Japan and United Kingdom. Suzanne Klise's co-authors include Roger R. Dmochowski, Claus G. Roehrborn, Stephen R. Kraus, Jed Kaminetsky, Lei Xu, John H. Krege, Sara M. Tolaney, Rashna Khanna, David Kudrow and Michael Case and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Suzanne Klise

18 papers receiving 417 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Suzanne Klise United States	11	275	168	143	109	94	18	435
E Silvestrini Italy	8	204 0.7×	199 1.2×	223 1.6×	51 0.5×	24 0.3×	9	428
A. Cilotti Italy	11	175 0.6×	90 0.5×	332 2.3×	28 0.3×	51 0.5×	19	599
Shuguang Piao South Korea	15	472 1.7×	198 1.2×	311 2.2×	34 0.3×	9 0.1×	23	652
Francisco Botelho Portugal	13	81 0.3×	197 1.2×	51 0.4×	129 1.2×	11 0.1×	52	519
Dulguun Batbold South Korea	11	157 0.6×	73 0.4×	90 0.6×	19 0.2×	13 0.1×	16	332
Kalyan Ghatak South Korea	12	184 0.7×	86 0.5×	89 0.6×	22 0.2×	6 0.1×	27	316
Emmanuel Weyne Belgium	15	244 0.9×	243 1.4×	95 0.7×	62 0.6×	5 0.1×	27	447
Anita Limanjaya South Korea	12	202 0.7×	82 0.5×	95 0.7×	21 0.2×	5 0.1×	27	332
Martyn A. Vickers United States	13	267 1.0×	139 0.8×	214 1.5×	69 0.6×	4 0.0×	20	451
Darby Stephens United States	4	360 1.3×	173 1.0×	281 2.0×	10 0.1×	14 0.1×	5	514

Countries citing papers authored by Suzanne Klise

Since Specialization

Citations

This map shows the geographic impact of Suzanne Klise's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Suzanne Klise with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Suzanne Klise more than expected).

Fields of papers citing papers by Suzanne Klise

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Suzanne Klise. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Suzanne Klise. The network helps show where Suzanne Klise may publish in the future.

Co-authorship network of co-authors of Suzanne Klise

This figure shows the co-authorship network connecting the top 25 collaborators of Suzanne Klise. A scholar is included among the top collaborators of Suzanne Klise based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Suzanne Klise. Suzanne Klise is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Wharton, Sean, Louis J. Aronne, Adam Stefański, et al.. (2025). Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. New England Journal of Medicine. 393(18). 1796–1806. 10 indexed citations

Ashina, Messoud, Uwe Reuter, Timothy R. Smith, et al.. (2021). Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia. 41(3). 294–304. 44 indexed citations

Brandes, Jan Lewis, Suzanne Klise, John H. Krege, et al.. (2020). Long-term safety and efficacy of lasmiditan for acute treatment of migraine: Final results of the GLADIATOR study. SHILAP Revista de lepidopterología. 3. 11 indexed citations

Brandes, Jan Lewis, David Kudrow, Suzanne Klise, et al.. (2019). Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR) (P1.10-021). Neurology. 92(15_supplement). 2 indexed citations

Brandes, Jan Lewis, Suzanne Klise, John H. Krege, et al.. (2019). Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia. 39(11). 1343–1357. 66 indexed citations

Tolaney, Sara M., Nancy U. Lin, Donald Thornton, et al.. (2017). Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.. Journal of Clinical Oncology. 35(15_suppl). 1019–1019. 41 indexed citations

Chiorean, E. Gabriela, Howard S. Höchster, Shivani Nanda, Donald Thornton, & Suzanne Klise. (2017). A phase II study of abemaciclib as a monotherapy and in combination with other agents in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 35(15_suppl). TPS4150–TPS4150. 5 indexed citations

Sahebjam, Solmaz, et al.. (2016). Assessment of concentrations of abemaciclib and its major active metabolites in plasma, CSF, and brain tumor tissue in patients with brain metastases secondary to hormone receptor positive (HR+) breast cancer.. Journal of Clinical Oncology. 34(15_suppl). 526–526. 19 indexed citations

Llombart‐Cussac, Antonio, Masakazu Toi, Suzanne Klise, et al.. (2015). Abstract OT1-1-07: A phase III study of abemaciclib (LY2835219) combined with fulvestrant in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer (MONARCH 2). Cancer Research. 75(9_Supplement). OT1–1. 8 indexed citations

10.

Goetz, Matthew P., Masakazu Toi, Suzanne Klise, et al.. (2015). MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).. Journal of Clinical Oncology. 33(15_suppl). TPS624–TPS624. 12 indexed citations

11.

Goldfischer, Evan R., John J. Kowalczyk, William R. Clark, et al.. (2012). Hemodynamic Effects of Once-daily Tadalafil in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant α1-Adrenergic Antagonist Therapy: Results of a Multicenter Randomized, Double-Blind, Placebo-controlled Trial. Urology. 79(4). 875–882. 25 indexed citations

12.

Dmochowski, Roger R., Claus G. Roehrborn, Suzanne Klise, et al.. (2012). Urodynamic Effects of Once Daily Tadalafil in Men With Lower Urinary Tract Symptoms Secondary to Clinical Benign Prostatic Hyperplasia: A Randomized, Placebo Controlled 12-Week Clinical Trial. The Journal of Urology. 189(1S). 18 indexed citations

13.

Kraus, Stephen R., Roger R. Dmochowski, Michael Albo, et al.. (2010). Urodynamic standardization in a large‐scale, multicenter clinical trial examining the effects of daily tadalafil in men with lower urinary tract symptoms with or without benign prostatic obstruction. Neurourology and Urodynamics. 29(5). 741–747. 12 indexed citations

14.

Dmochowski, Roger R., Claus G. Roehrborn, Suzanne Klise, et al.. (2010). Urodynamic Effects of Once Daily Tadalafil in Men With Lower Urinary Tract Symptoms Secondary to Clinical Benign Prostatic Hyperplasia: A Randomized, Placebo Controlled 12-Week Clinical Trial. The Journal of Urology. 183(3). 1092–1097. 95 indexed citations

15.

Dmochowski, Roger R., et al.. (2009). 471 URODYNAMIC EFFECTS OF TADALAFIL 20 MG ONCE DAILY VERSUS PLACEBO IN MEN WITH SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA. European Urology Supplements. 8(4). 238–238. 1 indexed citations

16.

Roehrborn, Claus G., Lei Xu, Roger R. Dmochowski, Stephen R. Kraus, & Suzanne Klise. (2009). REPRODUCIBILITY OF REPEAT URODYNAMIC ASSESSMENTS FROM A MULTICENTER TRIAL IN MEN WITH SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA FOLLOWING 12 WEEKS OF PLACEBO TREATMENT. The Journal of Urology. 181(4). 595–596. 1 indexed citations

17.

Dmochowski, Roger R., Claus G. Roehrborn, Stephen R. Kraus, Lei Xu, & Suzanne Klise. (2009). CHANGES IN BLADDER OUTLET OBSTRUCTION INDEX IN MEN WITH SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA TREATED WITH TADALAFIL. The Journal of Urology. 181(4). 695–696. 2 indexed citations

18.

Porst, Hartmut, Jacob Rajfer, Adolfo Casabé, et al.. (2008). Long-Term Safety and Efficacy of Tadalafil 5 mg Dosed Once Daily in Men with Erectile Dysfunction. The Journal of Sexual Medicine. 5(9). 2160–2169. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact